Systemic diseases and biotherapies: Understanding, evaluating, and preventing the risk of hepatitis B reactivation

Joint Bone Spine

Volumn 81, Issue 6, 2014, Pages 478-484

  Lunel Fabiani, Françoise ^a   Masson, Charles ^a   Ducancelle, Alexandra ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Biotherapies; HBsAg; HBV DNA; Hepatitis B; Immunosuppressive treatment; Rheumatoid arthritis; Spondyloarthritis; Systemic disease; TNF antagonists; Viral reactivation

Indexed keywords

ANTIVIRUS AGENT; CIRCULAR DNA; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA; HEPATITIS B VACCINE;

ANTIVIRAL THERAPY; BIOLOGICAL THERAPY; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HOST; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SEROLOGY; SYSTEMIC DISEASE; VACCINATION; VIROLOGY; VIRUS REACTIVATION; HEPATITIS B, CHRONIC; IMMUNOLOGY; RISK; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; BIOLOGICAL THERAPY; HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; RISK; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VIRUS ACTIVATION;

EID: 84922576890     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.01.015     Document Type: Short Survey

References (60)

1. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
2. Hoofnagle J.H. Reactivation of hepatitis B. Hepatology 2009, 49:S156-S165.
3. Lok A.S., Ward J.W., Perrillo R.P., et al. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med 2012, 156:743-745.
4. Adhikesavan L.G., Newman E.D., Diehl M.P., et al. American College of Rheumatology quality indicators for rheumatoid arthritis: benchmarking, variability, and opportunities to improve quality of care using the electronic health record. Arthritis Rheum 2008, 59:1705-1712.
5. Barclay S., Pol S., Mutimer D., et al. The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting. J Clin Virol 2008, 41:243-254. [Erratum: J Clin Virol 2008;42:104-5].
6. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185.
7. Pham T., Bachelez H., Berthelot J.M., et al. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011, 78:15-185.
8. Pham T., Claudepierre P., Constantin A., et al. Tocilizumab: therapy and safety management. Joint Bone Spine 2010, 77:S3-S100.
9. Pham T., Bachelez H., Berthelot J.M., et al. Abatacept therapy and safety management. Joint Bone Spine 2012, 79:3-84.
10. Terrier B., Pol S., Thibault V., et al. Prise en charge du risque de réactivation du virus de l'hépatite B chez les patients traités par immunosuppresseurs et immunomodulateurs en médecine interne: données de l'enquête REACTI-B et proposition d'un algorithme de prise en charge. Rev Med Interne 2012, 33:4-12.
11. Droz N., Gilardin L., Cacoub P., et al. Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. Arthritis Care Res (Hoboken) 2013, 65:1504-1514.
12. Locarnini S., Zoulim F. Molecular genetics of HBV infection. Antivir Ther 2010, 15:3-14.
13. Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009, 113:3147-3153.
14. Zoulim F., Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009, 137:1593-1608. [e1591-2].
15. Chao D., CHu K.Q. Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug Des Dev Ther 2013, 7:777-788.
16. Lok A.S., McMahon B.J. Chronic hepatitis B. Hepatology 2007, 45:507-539.
17. Carroll M.B., Bond M.I. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008, 38:208-217.
18. Hohler T., Kruger A., Gerken G., et al. A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 1998, 111:579-582.
19. Yeo W., Chan H.L. Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol 2012, 28:31-37.
20. Cassano N., Mastrandrea V., Principi M., et al. Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease. J Biol Regul Homeost Agents 2011, 25:285-289.
21. Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol 2011, 21:621-627.
22. Caporali R., Bobbio-Pallavicini F., Atzeni F., et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res (Hoboken) 2010, 62:749-754.
23. Chung S.J., Kim J.K., Park M.C., et al. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 2009, 36:2416-2420.
24. Loras C., Gisbert J.P., Minguez M., et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010, 59:1340-1346.
25. Tamori A., Koike T., Goto H., et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011, 46:556-564.
26. Mitroulis I., Hatzara C., Kandili A., et al. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2013, 72:308-310.
27. Vassilopoulos D., Apostolopoulou A., Hadziyannis E., et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2013, 69:1352-1355.
28. Chemin I., Guillaud O., Queyron P.C., et al. Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol 2009, 51:824-825.
29. Samal J., Kandpal M., Vivekanandan P. Molecular mechanisms underlying occult hepatitis B virus infection. Clin Microbiol Rev 2012, 25:142-163.
30. Vento S., Cainelli F., Longhi M.S. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002, 3:333-340.
31. Perez-Alvarez R., Diaz-Lagares C., Garcia-Hernandez F., et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 2011, 90:359-371.
32. Yeo W., Chan T.C., Leung N.W., et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009, 27:605-611.
33. Calabrese L.H., Zein N.N., Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006, 65:983-989.
34. Morisco F., Castiglione F., Rispo A., et al. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Dig Liver Dis 2011, 43:S40-S48.
35. Morisco F., Castiglione F., Rispo A., et al. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. J Viral Hepat 2013, 20:200-208.
36. Nielsen O.H., Ainsworth M.A. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med 2013, 369:754-762.
37. Wendling D., Di Martino V., Prati C., et al. Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine 2009, 76:308-311.
38. Salinas G.F., De Rycke L., Barendregt B., et al. Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis 2013, 72:1037-1043.
39. Wijaya I., Sanityoso A., Lesmana L.A. Acute liver failure related to chemotherapy. Acta Med Indones 2012, 44:145-149.
40. Abramson A., Menter A., Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. J Am Acad Dermatol 2012, 67:1349-1361.
41. Francois M., Alla F., Rabaud C., et al. Hepatitis B virus vaccination by French family physicians. Med Mal Infect 2013, 41:518-525.
42. Ansemant T., Ornetti P., Garrot J.F., et al. Usefulness of routine hepatitis C and hepatitis B serology in the diagnosis of recent-onset arthritis. Systematic prospective screening in all patients seen by the rheumatologists of a defined area-brief report. Joint Bone Spine 2012, 79:268-270.
43. Lok A.S., Lai C.L., Wu P.C. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology 1988, 8:766-770.
44. Borentain P., Colson P., Coso D., et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat 2010, 17:807-815.
45. Saag K.G., Teng G.G., Patkar N.M., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
46. Rahier J.F. Prevention and management of infectious complications in IBD. Dig Dis 2012, 30:408-414.
47. Runyon B.A. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009, 49:2087-2097.
48. Furst D.E., Keystone E.C., So A.K., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013, 72:ii2-ii34.
49. Goëb V., Arnaud L., Avouac J., et al. Conseils d'utilisation des traitements anti-TNF et recommandations nationales de bonne pratique labellisées par la Haute Autorité de santé française. Joint Bone Spine 2013, [doi.org/10.1016/j.jbspin.2013.09.001].
50. Loomba R., Rowley A., Wesley R., et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008, 148:519-528.
51. Katz L.H., Fraser A., Gafter-Gvili A., et al. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008, 15:89-102.
52. Lau G.K., Yiu H.H., Fong D.Y., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003, 125:1742-1749.
53. Hsu C., Hsiung C.A., Su I.J., et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008, 47:844-853.
54. Liu H.L., Zhao Z., Yang H., et al. The effects of nucleoside analogue prophylactic treatment on HBV activation in HBcAb+ patients undergoing immunosuppressive therapy. J Viral Hepat 2013, 20:645-649.
55. Lan J.L., Chen Y.M., Hsieh T.Y., et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2011, 70:1719-1725.
56. Fukushima N., Mizuta T., Tanaka M., et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009, 20:2013-2017.
57. Colson P., Borentain P., Coso D., et al. Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma. Br J Haematol 2008, 143:148-150.
58. Sanchez M.J., Buti M., Homs M., et al. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol 2009, 51:1091-1096.
59. Andres M., Courtney P. No hepatitis B reactivation in a patient with refractory antisynthesase syndrome successfully treated with rituximab. Joint Bone Spine 2011, 78:653-654.
60. Ghrénassia E., Mekinian A., Rouaghe S., et al. Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. Joint Bone Spine 2012, 79:100-101.